GB0318464D0 — Chemical compounds
Assigned to AstraZeneca AB · Expires 2003-09-10 · 23y expired
What this patent protects
A compound of the formula (1) or a pharmaceutically-acceptable salt wherein, for example, A is phenylene or heteroarylene; Y is selected from -C(O)R<SUP>2</SUP>, -C(O)OR<SUP>2</SUP>, -C(O)NR<SUP>2</SUP>R<SUP>3</SUP>, -(1-4C)alkyl [o…
USPTO Abstract
A compound of the formula (1) or a pharmaceutically-acceptable salt wherein, for example, A is phenylene or heteroarylene; Y is selected from -C(O)R<SUP>2</SUP>, -C(O)OR<SUP>2</SUP>, -C(O)NR<SUP>2</SUP>R<SUP>3</SUP>, -(1-4C)alkyl [optionally substituted]-(2-4C)alkenyl, -SO<SUB>2</SUB>NR<SUP>2</SUP>R<SUP>3</SUP>, and -S(O)<SUB>c</SUB>R<SUP>2 </SUP>(wherein c is 0, 1 or 2); compounds which possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of compounds and pharmaceutical compositions containing them are described.
Drugs covered by this patent
- Tradjenta (LINAGLIPTIN) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.